Comprehensive medication guide to Miebo including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0 with commercial insurance and the MIEBO MySavings copay card; Medicare Part D copay varies by plan (card not valid for Medicare). About 75% of commercial plans and 65% of Medicare Part D plans cover Miebo.
Estimated Cash Pricing
$800–$1,248 retail for a 3 mL bottle (30-day supply); as low as $778 with GoodRx or approximately $810 with SingleCare. No generic is available.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Miebo is the brand name for perfluorohexyloctane ophthalmic solution, a prescription eye drop manufactured by Bausch + Lomb. It was FDA-approved in May 2023 for the treatment of the signs and symptoms of dry eye disease (DED) in adults. Miebo contains 100% perfluorohexyloctane — it is entirely water-free and preservative-free, making it unlike any other dry eye medication on the market.
Miebo is the first and only FDA-approved prescription eye drop that directly targets tear evaporation, which is the leading cause of dry eye in approximately 9 out of 10 sufferers. While most prescription dry eye medications work by reducing inflammation to increase tear production, Miebo works differently — it forms a physical monolayer on the surface of the tear film to slow evaporation.
Miebo is classified as a semifluorinated alkane ophthalmic agent. It is particularly effective for patients with evaporative dry eye associated with meibomian gland dysfunction (MGD). There is no generic version of Miebo available as of 2026.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Miebo's active ingredient, perfluorohexyloctane (F6H8), is a semifluorinated alkane with a unique molecular structure that includes both fluorinated and hydrocarbon segments. This structure gives the molecule very low surface tension, allowing it to rapidly spread across the entire ocular surface when instilled.
Once spread, perfluorohexyloctane migrates to the air-liquid interface of the tear film — the outermost surface where tears meet the air. There, it forms a thin, orderly monolayer (a single-molecule-thick film) that acts as a physical barrier, reducing the rate at which the aqueous tear film evaporates beneath it. This mimics the function of healthy meibum (natural eye oil) secreted by the meibomian glands.
Because perfluorohexyloctane is entirely water-free, it does not support bacterial growth and requires no preservatives. It is not metabolized by liver enzymes and has very low systemic absorption after topical ocular use — meaning it stays where it's applied with no known drug interactions.
100% perfluorohexyloctane — ophthalmic solution
3 mL multi-dose bottle (~270 drops); one drop in each eye four times daily (QID); 30-day supply
Miebo is not on the FDA drug shortage list. However, some patients experience difficulty finding it at specific retail pharmacies. As a newer (approved 2023), brand-only drug with no generic and a high retail price ($800–$1,200 per bottle), some pharmacies don't carry it in their standard inventory unless they have consistent local demand.
Bausch + Lomb routes many Miebo prescriptions through BlinkRx digital pharmacy, which delivers nationally with free shipping. Patients can also use medfinder to check which local pharmacies currently have Miebo in stock, without calling each one individually.
Insurance coverage for Miebo is strong: approximately 75% of commercial plans, 65% of Medicare Part D plans, and nearly all Medicaid plans cover it as of January 2025. Prior authorization may be required. Eligible commercially insured patients may pay as little as $0 with the MIEBO MySavings copay card.
Because Miebo is not a controlled substance, any licensed prescriber with authority to prescribe non-scheduled medications can write a Miebo prescription. There are no DEA requirements, no special registration, and no mandatory REMS (Risk Evaluation and Mitigation Strategy) program.
Telehealth: Miebo can be prescribed via telehealth platforms for patients with an established dry eye diagnosis. However, most providers require at least one in-person exam to confirm the diagnosis and document findings needed for insurance prior authorization. The official Miebo website (miebo.com) includes a Doctor Locator tool to find eye care professionals in your area.
No. Miebo (perfluorohexyloctane ophthalmic solution) is not a controlled substance and has no DEA scheduling. It does not carry abuse potential, and there are no special prescribing, dispensing, or storage requirements related to controlled substance regulations.
Any licensed prescriber — including ophthalmologists, optometrists, primary care physicians, nurse practitioners, and physician assistants — can prescribe Miebo. It can also be prescribed via telehealth platforms in appropriate clinical contexts. Refills can be authorized at the time of the original prescription, and there are no limits on the number of refills from a regulatory standpoint.
Miebo is generally well-tolerated. In the GOBI and MOJAVE Phase 3 trials (over 1,200 patients), there were no serious ocular adverse events. The most common side effects were:
Know what you need? Skip the search.
Restasis (cyclosporine 0.05%)
Anti-inflammatory that reduces inflammation to increase natural tear production; been on market since 2002; generic available; takes 3–6 months for full effect; dosed twice daily
Xiidra (lifitegrast 5%)
Anti-inflammatory via LFA-1/ICAM-1 pathway; faster onset (~2–4 weeks); no generic; dosed twice daily; may cause altered taste
Cequa (cyclosporine 0.09%)
Higher-concentration cyclosporine with nanomicellar technology for better penetration; dosed twice daily; $89/month direct pricing available
Vevye (cyclosporine 0.1%)
Water-free cyclosporine in semifluorinated alkane vehicle; approved for DED signs and symptoms; generally well-tolerated; water-free and preservative-free
Tyrvaya (varenicline nasal spray)
Nasal spray that stimulates natural tear production via trigeminal nerve; no eye drops needed; dosed twice daily; option for patients who can't tolerate eye drops
Prefer Miebo? We can find it.
Other topical ophthalmic medications
minorNo pharmacological interaction, but apply Miebo last (5–10 minutes after other eye drops) to allow its protective monolayer to form undisturbed
Contact lenses
moderateDo not use while wearing contact lenses. Remove lenses before instillation and wait at least 30 minutes before reinserting. Miebo can coat lens material and affect clarity and fit.
Miebo represents a meaningful advance in dry eye therapy — not because it's more potent than prior drugs, but because it targets a different part of the pathophysiology. For the millions of patients with evaporative dry eye driven by meibomian gland dysfunction, Miebo offers something that cyclosporine and lifitegrast simply don't: a direct, physical mechanism to slow tear evaporation.
The main barriers to access are cost (brand-only, no generic) and variable retail pharmacy stocking. The MIEBO MySavings Program, BlinkRx, and robust insurance coverage reduce the cost burden for most patients. For those who still struggle to find it at a nearby pharmacy, the best strategies are asking for BlinkRx delivery or using a pharmacy search tool.
If you're having trouble finding Miebo at a local pharmacy, medfinder can help you identify which pharmacies near you currently have it in stock — no phone calls required.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini